- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02932566
The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE)
A Randomised, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Greater Manchester
-
Manchester, Greater Manchester, United Kingdom, M23 9LT
- Manchester University NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent.
- Male or female; aged 40 years or older.
HF, defined as one symptom present at the time of screening, and one sign present at the time of screening or in the previous 12 months. Symptoms and signs are defined as:
Symptoms: dyspnoea on exertion, orthopnoea or paroxysmal nocturnal dyspnoea Signs: peripheral oedema, crackles on chest auscultation post-cough, raised jugular venous pressure or chest x-ray demonstrating pleural effusion, pulmonary congestion, or cardiomegaly
- Left Ventricular Ejection Fraction (LVEF) > 45% at Visit 0, (any local LVEF measurement made using echocardiography or CMR).
- BNP ≥ 100 pg/ml or NTproBNP ≥ 300 pg/ml recorded at Visit 0. For patients in atrial fibrillation on Visit 0 ECG, BNP > 300pg/ml or NTproBNP > 900 pg/ml at Visit 0.
- Myocardial fibrosis, defined as Extracellular Matrix (ECM) volume > 27% by CMR at Visit 0.
Exclusion Criteria:
- Myocardial infarction, coronary artery bypass graft surgery or percutaneous coronary intervention within the previous 6 months.
Probable alternative cause of patient's HF symptoms that in the opinion of the investigator primarily accounts for patient's dyspnoea such as significant pulmonary disease, anaemia or obesity. Specifically, patients with the below are excluded:
- Severe chronic obstructive pulmonary disease (COPD) (i.e., requiring home oxygen, chronic nebuliser therapy, or chronic oral steroid therapy), or
- Haemoglobin < 9 g/dl, or
- Body mass index (BMI) > 55 kg/m2.
- Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy.
- Clinically significant congenital heart disease.
- Presence of severe valvular heart disease.
- Atrial fibrillation or flutter with a resting ventricular rate > 100 bpm.
- Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
- Severe renal dysfunction at Visit 0, defined as estimated Glomerular Filtration Rate (eGFR) <30 mL/min (using Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI) calculation), or end-stage renal disease requiring dialysis.
- History of severe hepatic impairment or liver dysfunction at Visit 0, defined as total bilirubin above the upper limit of normal (ULN) (excluding patients with Gilbert's syndrome), aspartate aminotransferase (AST) or alanine transaminase (ALT) >3 times the ULN or alkaline phosphatase >2.5 times the ULN.
- Prolonged corrected QT interval, defined as a corrected QT interval >500 msec on ECG using Bazett formula.
- Known hypersensitivity to any of the components of the investigational medicinal product (IMP).
- Use of other investigational drugs at the time of enrolment, or within 30 days or 5 half-lives of enrolment, whichever is longer.
- Fluvoxamine use within 28 days of Visit 0.
- Contraindication to MRI scanning or gadolinium-based contrast agent
- Pregnancy, lactation or planning pregnancy. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment, must agree to pregnancy tests at study visits as defined in the Section 7.2.5 and must agree to maintain highly effective contraception during the study and for 3 months thereafter. Similarly male participants with female partners of childbearing potential must agree to maintain highly effective contraception during the study and for 3 months thereafter.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pirfenidone
Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
|
Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
Other Names:
|
Placebo Comparator: Placebo
Placebo capsule by mouth, three times a day (target dose) for 12 months
|
Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extracellular volume fraction (ECV)
Time Frame: 12 months
|
Absolute change in myocardial ECV, measured using CMR, from baseline to week 52
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left ventricular (LV) mass
Time Frame: 12 months
|
Absolute change in LV mass, measured using CMR, from baseline to week 52.
|
12 months
|
Left ventricular volume
Time Frame: 12 months
|
Absolute change in LV volume, measured using CMR, from baseline to week 52.
|
12 months
|
Left ventricular ejection fraction
Time Frame: 12 months
|
Absolute change in LV ejection fraction, measured using CMR, from baseline to week 52.
|
12 months
|
Left ventricular strain - CMR
Time Frame: 12 months
|
Absolute change in LV strain, measured using CMR, from baseline to week 52.
|
12 months
|
Left ventricular strain - Echo
Time Frame: 12 months
|
Absolute change in LV strain, measured using echocardiography, from baseline to week 52.
|
12 months
|
Left ventricular torsion
Time Frame: 12 months
|
Absolute change in LV torsion, measured using echocardiography, from baseline to week 52.
|
12 months
|
Myocardial cell structure
Time Frame: 12 months
|
Absolute change myocardial cell volume, measured using CMR, from baseline to week 52.
|
12 months
|
Diastolic function
Time Frame: 12 months
|
Absolute change in LV diastolic function, measured using echocardiography, from baseline to week 52.
|
12 months
|
Left atrial volume
Time Frame: 12 months
|
Absolute change in left atrial volume, measured using CMR, from baseline to week 52.
|
12 months
|
Myocardial energetic status
Time Frame: 12 months
|
Absolute change in myocardial energetic status (Phosphocreatine (PCr) to adenosine triphosphate (ATP) ratio), measured using Phosphorus-31 Magnetic Resonance Spectroscopy (31P MRS), from baseline to week 52.
|
12 months
|
Cardiac biomarkers - N-Terminal-Pro-Brain Natriuretic Peptide (NT-Pro BNP)
Time Frame: 12 months
|
Absolute change in NT-Pro BNP from baseline to week 13, baseline to week 26 and baseline to week 52.
|
12 months
|
Cardiac biomarkers - high-sensitivity Troponin T (hsTnT)
Time Frame: 12 months
|
Absolute change in hsTnT from baseline to week 13, baseline to week 26 and baseline to week 52.
|
12 months
|
Patient exercise capacity
Time Frame: 12 months
|
Absolute change in exercise tolerance, measured using 6 minute walk distance, from baseline to week 52.
|
12 months
|
Patient morbidity
Time Frame: 12 months
|
Absolute change in health status (quality of life), HF symptoms and physical limitations, measured using change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score, from baseline to week 52
|
12 months
|
All cause mortality
Time Frame: 12 months
|
All cause mortality will be recorded but the trial is not powered for this clinical outcome
|
12 months
|
Cardiovascular mortality
Time Frame: 12 months
|
Cardiovascular mortality will be recorded but the trial is not powered for this clinical outcome
|
12 months
|
Hospitalisation for heart failure
Time Frame: 12 months
|
Hospitalisation for heart failure will be recorded but the trial is not powered for this clinical outcome
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christopher A Miller, MBChB, PhD, University of Manchester
Publications and helpful links
General Publications
- King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum In: N Engl J Med. 2014 Sep 18;371(12):1172.
- Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8.
- Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve. 2006 Sep;34(3):327-34. doi: 10.1002/mus.20590.
- Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiota M, Hanatani A, Shimada K, Muro T, Iwao H, Yoshiyama M. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res. 2012 Jan;35(1):34-40. doi: 10.1038/hr.2011.139. Epub 2011 Aug 25.
- Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013;126(1):1-11. doi: 10.1159/000351179. Epub 2013 Jul 2.
- Lewis GA, Rosala-Hallas A, Dodd S, Schelbert EB, Williams SG, Cunnington C, McDonagh T, Miller CA. Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone. J Am Heart Assoc. 2022 Jul 19;11(14):e024668. doi: 10.1161/JAHA.121.024668. Epub 2022 Jul 13.
- Lewis GA, Rosala-Hallas A, Dodd S, Schelbert EB, Williams SG, Cunnington C, McDonagh T, Miller CA. Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction. J Cardiovasc Transl Res. 2022 Jul 5. doi: 10.1007/s12265-022-10264-7. Online ahead of print.
- Lewis GA, Rosala-Hallas A, Dodd S, Schelbert EB, Williams SG, Cunnington C, McDonagh T, Miller CA. Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction. Int J Cardiovasc Imaging. 2022 Feb 9. doi: 10.1007/s10554-022-02544-9. Online ahead of print.
- Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, Naish JH, Jimenez BD, Williams SG, Cunnington C, Ahmed FZ, Cooper A, Rajavarma Viswesvaraiah, Russell S, McDonagh T, Williamson PR, Miller CA. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med. 2021 Aug;27(8):1477-1482. doi: 10.1038/s41591-021-01452-0. Epub 2021 Aug 12.
- Lewis GA, Schelbert EB, Naish JH, Bedson E, Dodd S, Eccleson H, Clayton D, Jimenez BD, McDonagh T, Williams SG, Cooper A, Cunnington C, Ahmed FZ, Viswesvaraiah R, Russell S, Neubauer S, Williamson PR, Miller CA. Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial. Cardiovasc Drugs Ther. 2019 Aug;33(4):461-470. doi: 10.1007/s10557-019-06876-y.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016CD004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Failure
-
Lexicon PharmaceuticalsSanofiTerminatedCardiac Failure AggravatedUnited States, Canada, Netherlands
-
Baylor Research InstituteCompleted
-
University of MilanFondazione Salvatore MaugeriCompletedHyperinflation | COPD | Right Cardiac FailureItaly
-
Aretaieion University HospitalCompletedCardiac Surgery | Cardiac Disease | Cardiac Failure | Inotropes | Ejection FractionGreece
-
Biobeat Technologies Ltd.CompletedAcute Cardiac Event | Acute Cardiac Failure | Acute Cardiac Pulmonary EdemaIsrael
-
Universitair Ziekenhuis BrusselUnknownSepsis | Cardiac Failure AcuteBelgium
-
Centro Hospitalar do PortoCompletedDecompensated Heart Failure | Functional Cardiac DisorderPortugal
-
Universidade do PortoInstituto Politécnico de Bragança; Centro Hospitalar do PortoCompletedDecompensated Heart Failure | Functional Cardiac DisorderPortugal
-
Otsuka Pharmaceutical Co., Ltd.RecruitingCardiac Edema (CHF)Japan
-
Bristol-Myers SquibbCompletedCardiac Failure | Myocardial FailureUnited States
Clinical Trials on Pirfenidone
-
Jorge L PooCompletedCirrhosis, Liver | Liver Fibrosis | Chronic Liver Disease
-
Capital Medical UniversityActive, not recruiting
-
Fujian Medical University Union HospitalBeijing Continent Pharmaceutical Co, Ltd.RecruitingAcute Lung Injury | PreventionChina
-
Huilan ZhangUnknownPneumonia | Novel Coronavirus Pneumonia | PirfenidoneChina
-
Beijing Continent Pharmaceutical Co, Ltd.Recruiting
-
Genentech, Inc.Hoffmann-La RocheCompletedIdiopathic Pulmonary FibrosisUnited States
-
Hospices Civils de LyonRecruitingProgressive Idiopathic Pulmonary FibrosisFrance
-
Stanford UniversityGenentech, Inc.CompletedBronchiolitis Obliterans | Graft Vs Host DiseaseUnited States
-
Instituto de investigación e innovación biomédica...RecruitingSilicosis | Progressive Massive Fibrosis | Complicated SilicosisSpain
-
Zagazig UniversityCompletedHypersensitivity PneumonitisEgypt